Frequency Therapeutics (NASDAQ:FREQ) made its public debut Thursday morning, opening at $11.20 after being priced at $14 per share.
The company shares are trading on the Nasdaq under the ticker “FREQ.”
Frequency Therapeutics is a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases.
JPMorgan, Goldman Sachs and Cowen are acting as joint book running managers for the offering.
Related Links:
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
